Pancreatic Cancer Research

ResearcherTokai UniversityActive in the last 2 years

Taro Mashiko

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7398-2936; OpenAlex author ID A5035083980. Sources: OpenAlex.

Their work

Papers
5 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 5

  1. Low Pretreatment CALLY Index Predicts Early Recurrence in Resected UICC Stage I Pancreatic Ductal Adenocarcinoma. Co-author PMID 40105230↗
  2. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocar… Co-author DOI 10.5009/gnl220311↗
  3. Significance of pulmonary resection in patients with metachronous pulmonary metastasis from pancreatic ductal adenocarcinoma: a retrospective cohort study. Co-author DOI 10.1186/s12893-021-01236-w↗
  4. [Multidisciplinary Therapy for Unresectable Pancreatic Cancer]. Co-author PMID 33130694↗
  5. Conversion surgery for an initially unresectable, locally advanced pancreatic cancer after induction chemotherapy and carbon-ion radiotherapy: a case report. First author DOI 10.1186/s40792-018-0522-4↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toshio Nakagohri · 5 shared papers, 2018–2025 · strength 0.85
  2. Shigenori Ei · 2 shared papers, 2023–2025 · strength 0.47
  3. Shinichiro Takahashi · 2 shared papers, 2023–2025 · strength 0.47
  4. Masaki Mori · 1 shared paper, 2025 · strength 0.26
  5. Misuzu Yamada · 1 shared paper, 2018 · strength 0.08
  6. Takeshi Fujishiro · 1 shared paper, 2018 · strength 0.08
  7. Kenichi Hirabayashi · 1 shared paper, 2018 · strength 0.08
  8. Masami Ogawa · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.